“The data being presented at AAN illustrate the breadth of Biogen Idec’s ongoing commitment to the MS community,” said Douglas E. Williams, Ph.D., executive vice president, research and development at Biogen Idec. “MS affects each person differently and, until we find a cure, Biogen Idec is dedicated to driving ground-breaking research and pursuing highly differentiated therapies. Our leading marketed products, TYSABRI and AVONEX continue to remain gold-standards of care in the treatment and management of MS. Our robust pipeline has the potential to offer effective and convenient therapies targeting the different pathways of the disease, addressing the unique needs of each individual MS patient.”
The following represents select data highlights during the meeting from the Company’s portfolio of marketed products.
TYSABRI
Key TYSABRI data being presented at the Congress includes:
– Assessment of Baseline Treatment History and Postbaseline Relapses and Serious Adverse Events in MS Patients Treated with Natalizumab – S51.005
– Risk Stratification for Progressive Multifocal Leukoencephalopathy (PML) in MS Patients: Role of Prior Immunosuppressant Use, Natalizumab-Treatment Duration, and Anti-JCV Antibody Status – P03.248
– Assessment of the Association Between Baseline Characteristics and Postbaseline Relapses, Disability Progression and Improvement over Time in the Natalizumab (TYSABRI) Observational Program (TOP) in Patients with Multiple Sclerosis – P01.199
– Patient-Reported Disability Level and Functional Status: Impact after One Year of Natalizumab Treatment – P07.155
– Effects of Natalizumab on Cognition in Multiple Sclerosis: Findings from the ENER-G Study – P06.077
-Effects of Natalizumab on Bladder Function: Interim Results of the TRUST Study – PD06.009
AVONEX
Key AVONEX data being presented at the Congress includes:
– Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis – P06.040
– Association between Changes in Gray Matter MRI Measures and Disability Progression over 5 Years in Patients Treated with IM IFNB-1a – P05.058
Dr. Williams continued, “Over the last several years, we have consistently expanded and redefined patients’ expectations for successful management of their multiple sclerosis. We continue to make significant investments in the discovery and development of new treatments, while remaining committed to increasing the safety and efficacy of available therapies. As a company, we recognize the unmet need that remains within the MS community and believe that no one is doing more to address it than Biogen Idec.”
The following represents select data highlights during the meeting from the Company’s late-stage MS portfolio.
FAMPYRA (prolonged-release fampridine tablets)
Key FAMPYRA data being presented at the Congress includes:
.
***************************************************************************************
.
.